Amphstar Pharmaceuticals
AMPH · Pharmaceuticals
$25.14
3.5%Corcept Therapeutics
CORT · Pharmaceuticals
$85.86
20.1%The short version
- Corcept Therapeutics is the larger business, with $761M of revenue in fiscal 2025 against $720M for Amphstar Pharmaceuticals.
- Corcept Therapeutics grew revenue faster (12.8%, against −1.7%).
- Amphstar Pharmaceuticals kept more of each dollar of sales as operating profit (19.5% operating margin, against 5.9% operating margin).
- Corcept Therapeutics turned more of its sales into free cash flow (18.6% FCF margin, against 16.8% FCF margin).
- Corcept Therapeutics earned a higher return on the capital invested in it (15.7%, against 9.9%).
| Latest fiscal year | AMPH · FY25 | CORT · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.1B | $10.2B |
| Revenue | $720M | $761M |
| Free cash flow | $121M | $142M |
| Net income | $98.1M | $99.7M |
| Growth | ||
| Revenue growth | −1.7% | 12.8% |
| 5-year growth | 15.5% | 16.6% |
| Share count change | −7.4% | 5.7% |
| Profitability | ||
| Gross margin | 49.5% | 98.3% |
| Operating margin | 19.5% | 5.9% |
| Net margin | 13.6% | 13.1% |
| FCF margin | 16.8% | 18.6% |
| Return on capital | 9.9% | 15.7% |
| Return on equity | 12.9% | 15.0% |
| Balance sheet | ||
| Net debt | $339M | −$372M |
| Net debt / EBITDA | 1.7x | −8.1x |
| Dividends and buybacks | $75.6M | $173M |
| Valuation & quality | ||
| P/E | 14.9x | — |
| Piotroski F-score | 6 | 3 |
FY16
AMPH $255M
CORT $81.3M
FY17
AMPH $240M
CORT $159M
FY18
AMPH $295M
CORT $251M
FY19
AMPH $322M
CORT $307M
FY20
AMPH $350M
CORT $354M
FY21
AMPH $438M
CORT $366M
FY22
AMPH $499M
CORT $402M
FY23
AMPH $644M
CORT $482M
FY24
AMPH $732M
CORT $675M
FY25
AMPH $720M
CORT $761M
AMPH
CORT
FY16
AMPH 6.0%
CORT 12.5%
FY17
AMPH −0.5%
CORT 33.2%
FY18
AMPH −2.9%
CORT 35.6%
FY19
AMPH −0.0%
CORT 36.4%
FY20
AMPH 3.1%
CORT 36.2%
FY21
AMPH 16.0%
CORT 34.0%
FY22
AMPH 21.5%
CORT 28.0%
FY23
AMPH 30.6%
CORT 22.2%
FY24
AMPH 28.1%
CORT 20.3%
FY25
AMPH 19.5%
CORT 5.9%
AMPH
CORT
FY16
AMPH $17.2M
CORT $18.2M
FY17
AMPH $4.1M
CORT $60.5M
FY18
AMPH −$8.6M
CORT $115M
FY19
AMPH $0.2M
CORT $135M
FY20
AMPH $23.4M
CORT $151M
FY21
AMPH $70.5M
CORT $167M
FY22
AMPH $65.2M
CORT $120M
FY23
AMPH $145M
CORT $127M
FY24
AMPH $172M
CORT $196M
FY25
AMPH $121M
CORT $142M
AMPH
CORT
FY16
AMPH 3.7%
CORT —
FY17
AMPH −0.4%
CORT 99.0%
FY18
AMPH −2.1%
CORT 85.5%
FY19
AMPH −0.0%
CORT 109.6%
FY20
AMPH 1.4%
CORT 116.1%
FY21
AMPH 13.4%
CORT 95.4%
FY22
AMPH 20.9%
CORT 88.4%
FY23
AMPH 22.6%
CORT 87.6%
FY24
AMPH 16.4%
CORT 55.1%
FY25
AMPH 9.9%
CORT 15.7%
AMPH
CORT
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.